XOMA Royalty Future Growth
Future criteria checks 5/6
XOMA Royalty is forecast to grow earnings and revenue by 27% and 24.7% per annum respectively while EPS is expected to grow by 17.3% per annum.
Key information
27.0%
Earnings growth rate
17.29%
EPS growth rate
| Biotechs earnings growth | 23.3% |
| Revenue growth rate | 24.7% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 20 Mar 2026 |
Recent future growth updates
Recent updates
Royalty Financing Expansion And Diversified Biotech Portfolio Will Support Long Term Upside
Catalysts About XOMA Royalty XOMA Royalty acquires and manages a diversified portfolio of biotechnology royalties and milestone interests across the drug development spectrum. What are the underlying business or industry changes driving this perspective?
Expanding Royalty Portfolio And Funded Pipelines Will Reshape Long Term Earnings Quality
Catalysts About XOMA Royalty XOMA Royalty builds and manages a diversified portfolio of biotechnology royalty and milestone interests across the drug development cycle. What are the underlying business or industry changes driving this perspective?
Future Royalty Concentration And Litigation Risks May Eventually Reward Patient Holders
Catalysts About XOMA Royalty XOMA Royalty aggregates biotechnology royalty and milestone interests across the drug development spectrum, aiming to build a diversified, cash generative portfolio funded largely by third party R&D spend. What are the underlying business or industry changes driving this perspective?Investors Don't See Light At End Of XOMA Royalty Corporation's (NASDAQ:XOMA) Tunnel
Dec 15
XOMA Royalty PFD Update: Going Back To My Original Sell Ratings
Oct 03XOMA Royalty Corporation's (NASDAQ:XOMA) Shares Climb 27% But Its Business Is Yet to Catch Up
Aug 21XOMA Royalty Corporation's (NASDAQ:XOMA) 27% Share Price Surge Not Quite Adding Up
May 08XOMA Royalty (NASDAQ:XOMA) Is Making Moderate Use Of Debt
Apr 16Risks Still Elevated At These Prices As XOMA Royalty Corporation (NASDAQ:XOMA) Shares Dive 25%
Mar 14XOMA Royalty's Preferred Shares: High-Yield Dividends From Biotech Royalties
Oct 15News Flash: Analysts Just Made A Notable Upgrade To Their XOMA Royalty Corporation (NASDAQ:XOMA) Forecasts
Aug 14Health Check: How Prudently Does XOMA Royalty (NASDAQ:XOMA) Use Debt?
Aug 02XOMA Corporation: A Hold Rating With Steady Income From Preferred Shares
Jun 29Is XOMA (NASDAQ:XOMA) Using Debt Sensibly?
Apr 03Are Investors Undervaluing XOMA Corporation (NASDAQ:XOMA) By 49%?
Sep 01Bearish: Analysts Just Cut Their XOMA Corporation (NASDAQ:XOMA) Revenue and EPS estimates
Aug 11XOMA GAAP EPS of -$0.53 misses by $0.37, revenue of $0.98M misses by $3.29M
Aug 04Forecast: Analysts Think XOMA Corporation's (NASDAQ:XOMA) Business Prospects Have Improved Drastically
May 08Xoma Gets The Spotlight
Sep 02Things Look Grim For XOMA Corporation (NASDAQ:XOMA) After Today's Downgrade
Aug 20We Think The Compensation For XOMA Corporation's (NASDAQ:XOMA) CEO Looks About Right
May 13Does XOMA (NASDAQ:XOMA) Have A Healthy Balance Sheet?
May 11XOMA's (NASDAQ:XOMA) Earnings Are Of Questionable Quality
Mar 17Analysts Are More Bearish On XOMA Corporation (NASDAQ:XOMA) Than They Used To Be
Mar 16Is XOMA Corporation (NASDAQ:XOMA) Popular Amongst Institutions?
Mar 09Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2028 | 133 | 34 | 147 | N/A | 3 |
| 12/31/2027 | 89 | 13 | 79 | N/A | 3 |
| 12/31/2026 | 66 | 16 | 55 | N/A | 5 |
| 12/31/2025 | 52 | 19 | -18 | 3 | N/A |
| 9/30/2025 | 47 | 10 | -15 | 5 | N/A |
| 6/30/2025 | 45 | -16 | -23 | -3 | N/A |
| 3/31/2025 | 43 | -9 | -7 | -7 | N/A |
| 12/31/2024 | 28 | -19 | -14 | -14 | N/A |
| 9/30/2024 | 22 | -35 | -15 | -15 | N/A |
| 6/30/2024 | 15 | -24 | -8 | -8 | N/A |
| 3/31/2024 | 6 | -42 | -18 | -18 | N/A |
| 12/31/2023 | 5 | -46 | -18 | -18 | N/A |
| 9/30/2023 | 4 | -32 | -18 | -18 | N/A |
| 6/30/2023 | 4 | -31 | -20 | -20 | N/A |
| 3/31/2023 | 3 | -30 | -17 | -17 | N/A |
| 12/31/2022 | 6 | -23 | -13 | -13 | N/A |
| 9/30/2022 | 40 | 10 | 42 | 22 | N/A |
| 6/30/2022 | 41 | 10 | 36 | 22 | N/A |
| 3/31/2022 | 41 | 12 | 36 | 23 | N/A |
| 12/31/2021 | 38 | 8 | 23 | 23 | N/A |
| 9/30/2021 | 30 | 1 | -11 | 10 | N/A |
| 6/30/2021 | 29 | 6 | -3 | 10 | N/A |
| 3/31/2021 | 29 | 6 | -2 | 11 | N/A |
| 12/31/2020 | 29 | 9 | 10 | 10 | N/A |
| 9/30/2020 | 2 | -13 | -12 | -12 | N/A |
| 6/30/2020 | 11 | -9 | -18 | -5 | N/A |
| 3/31/2020 | 11 | -10 | -25 | -6 | N/A |
| 12/31/2019 | 18 | -2 | -20 | 0 | N/A |
| 9/30/2019 | 20 | -2 | N/A | 1 | N/A |
| 6/30/2019 | 12 | -8 | N/A | -5 | N/A |
| 3/31/2019 | 13 | -6 | N/A | -6 | N/A |
| 12/31/2018 | 5 | -13 | N/A | -13 | N/A |
| 9/30/2018 | 9 | -11 | N/A | -15 | N/A |
| 6/30/2018 | 44 | 9 | N/A | 18 | N/A |
| 3/31/2018 | 53 | 18 | N/A | 13 | N/A |
| 12/31/2017 | 53 | 6 | N/A | 3 | N/A |
| 9/30/2017 | 48 | -11 | N/A | 15 | N/A |
| 6/30/2017 | 12 | -39 | N/A | -28 | N/A |
| 3/31/2017 | 2 | -61 | N/A | -32 | N/A |
| 12/31/2016 | 6 | -54 | N/A | -34 | N/A |
| 9/30/2016 | 53 | -11 | N/A | -12 | N/A |
| 6/30/2016 | 55 | 1 | N/A | -19 | N/A |
| 3/31/2016 | 57 | -7 | N/A | -23 | N/A |
| 12/31/2015 | 55 | -21 | N/A | -31 | N/A |
| 9/30/2015 | 12 | -53 | N/A | -77 | N/A |
| 6/30/2015 | 15 | -67 | N/A | -74 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: XOMA's forecast earnings growth (27% per year) is above the savings rate (3.4%).
Earnings vs Market: XOMA's earnings (27% per year) are forecast to grow faster than the US market (15.9% per year).
High Growth Earnings: XOMA's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: XOMA's revenue (24.7% per year) is forecast to grow faster than the US market (10.9% per year).
High Growth Revenue: XOMA's revenue (24.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if XOMA's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/23 03:42 |
| End of Day Share Price | 2026/04/23 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
XOMA Royalty Corporation is covered by 13 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Wasserman | Benchmark Company |
| Ritu Baral | Canaccord Genuity |
| Joseph Pantginis | H.C. Wainwright & Co. |